Challenges to sovereign ambitions: forces of convergence and divergence within the global pharmaceutical sector and the UK's withdrawal from the European Union.
- Publisher:
- Cambridge University Press (CUP)
- Publication Type:
- Journal Article
- Citation:
- Health Econ Policy Law, 2021, 16, (3), pp. 256-272
- Issue Date:
- 2021-07
Closed Access
Filename | Description | Size | |||
---|---|---|---|---|---|
Challenges_to_sovereign_ambiti.pdf | Published version | 216.19 kB | Adobe PDF |
Copyright Clearance Process
- Recently Added
- In Progress
- Closed Access
This item is closed access and not available.
Full metadata record
Field | Value | Language |
---|---|---|
dc.contributor.author | Wright, JSF | |
dc.contributor.author | Doukas, D | |
dc.date.accessioned | 2023-04-04T00:27:17Z | |
dc.date.available | 2023-04-04T00:27:17Z | |
dc.date.issued | 2021-07 | |
dc.identifier.citation | Health Econ Policy Law, 2021, 16, (3), pp. 256-272 | |
dc.identifier.issn | 1744-1331 | |
dc.identifier.issn | 1744-134X | |
dc.identifier.uri | http://hdl.handle.net/10453/169091 | |
dc.description.abstract | This paper maps key regulatory, governance and legal challenges associated with the UK's withdrawal from the European Union (EU) in terms of convergent and divergent pressures within the global pharmaceutical sector. These include (i) convergent regulatory pressures associated with the European framework for pre-market licensing; (ii) convergent and divergent industry pressures with regard to drug discovery and manufacturing; and (iii) divergent and convergent market pressures associated with the supply, pricing and assessment of medicines. The UK's sovereign ambitions risk a loss of influence over the licensing and surveillance of pharmaceuticals under convergent regulatory and industry pressures to engage in unilateral participation in the European regime. Further, they also risk a loss of influence over processes for pricing and assessing the effectiveness of new treatment regimens under divergent market pressures from larger pharmaceutical markets outside the EU, notably the United States. | |
dc.format | Print-Electronic | |
dc.language | eng | |
dc.publisher | Cambridge University Press (CUP) | |
dc.relation.ispartof | Health Econ Policy Law | |
dc.relation.isbasedon | 10.1017/S174413312000016X | |
dc.rights | info:eu-repo/semantics/closedAccess | |
dc.subject | 1402 Applied Economics, 1605 Policy and Administration, 1801 Law | |
dc.subject.classification | Health Policy & Services | |
dc.subject.mesh | Commerce | |
dc.subject.mesh | Drug Industry | |
dc.subject.mesh | European Union | |
dc.subject.mesh | Health Care Sector | |
dc.subject.mesh | Intellectual Property | |
dc.subject.mesh | International Law | |
dc.subject.mesh | Pharmaceutical Preparations | |
dc.subject.mesh | United Kingdom | |
dc.subject.mesh | United States | |
dc.subject.mesh | Pharmaceutical Preparations | |
dc.subject.mesh | European Union | |
dc.subject.mesh | Intellectual Property | |
dc.subject.mesh | Commerce | |
dc.subject.mesh | Drug Industry | |
dc.subject.mesh | Health Care Sector | |
dc.subject.mesh | United States | |
dc.subject.mesh | International Law | |
dc.subject.mesh | United Kingdom | |
dc.subject.mesh | Commerce | |
dc.subject.mesh | Drug Industry | |
dc.subject.mesh | European Union | |
dc.subject.mesh | Health Care Sector | |
dc.subject.mesh | Intellectual Property | |
dc.subject.mesh | International Law | |
dc.subject.mesh | Pharmaceutical Preparations | |
dc.subject.mesh | United Kingdom | |
dc.subject.mesh | United States | |
dc.title | Challenges to sovereign ambitions: forces of convergence and divergence within the global pharmaceutical sector and the UK's withdrawal from the European Union. | |
dc.type | Journal Article | |
utslib.citation.volume | 16 | |
utslib.location.activity | England | |
utslib.for | 1402 Applied Economics | |
utslib.for | 1605 Policy and Administration | |
utslib.for | 1801 Law | |
pubs.organisational-group | /University of Technology Sydney | |
pubs.organisational-group | /University of Technology Sydney/DVC (Research) | |
pubs.organisational-group | /University of Technology Sydney/DVC (Research)/lnstitute for Public Policy and Governance | |
pubs.organisational-group | /University of Technology Sydney/Strength - IPPG - Institute for Public Policy and Governance | |
utslib.copyright.status | closed_access | * |
dc.date.updated | 2023-04-04T00:27:16Z | |
pubs.issue | 3 | |
pubs.publication-status | Published | |
pubs.volume | 16 | |
utslib.citation.issue | 3 |
Abstract:
This paper maps key regulatory, governance and legal challenges associated with the UK's withdrawal from the European Union (EU) in terms of convergent and divergent pressures within the global pharmaceutical sector. These include (i) convergent regulatory pressures associated with the European framework for pre-market licensing; (ii) convergent and divergent industry pressures with regard to drug discovery and manufacturing; and (iii) divergent and convergent market pressures associated with the supply, pricing and assessment of medicines. The UK's sovereign ambitions risk a loss of influence over the licensing and surveillance of pharmaceuticals under convergent regulatory and industry pressures to engage in unilateral participation in the European regime. Further, they also risk a loss of influence over processes for pricing and assessing the effectiveness of new treatment regimens under divergent market pressures from larger pharmaceutical markets outside the EU, notably the United States.
Please use this identifier to cite or link to this item:
Download statistics for the last 12 months
Not enough data to produce graph